Research of Mucocutaneous Lymph Node Syndrome has been linked to Aneurysm, Coronary Aneurysm, Vasculitis, Coronary Heart Disease, Lymphatic Diseases. The study of Mucocutaneous Lymph Node Syndrome has been mentioned in research publications which can be found using our bioinformatics tool below. Researched pathways related to Mucocutaneous Lymph Node Syndrome include Pathogenesis, Immune Response, Inflammatory Response, Secretion, Cytokine Production. These pathways complement our catalog of research reagents for the study of Mucocutaneous Lymph Node Syndrome including antibodies and ELISA kits against TNF, CRP, FH, CLEC4D, IL6.
Laverne is a handy bioinformatics tool to help facilitate scientific exploration of related genes, diseases and pathways based on co-citations. Explore more on Mucocutaneous Lymph Node Syndrome below!
For more information on how to use Laverne, please read the How to Guide.
We have 4652 products for the study of Mucocutaneous Lymph Node Syndrome that can be applied to Western Blot, Flow Cytometry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry from our catalog of antibodies and ELISA kits.
Mucocutaneous Lymph Node Syndrome is also known as Acute Febrile Mucocutaneous Lymph Node Syndrome, Acute Febrile Mucocutaneous Lymph Node Syndrome (mcls), Kawasaki Disease, Kawasaki Syndrome, Kawasaki's Disease.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.